Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KMDA with free AI briefings, catalyst countdowns, and dilution alerts.

KMDA · KAMADA LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$75.3M Cash on Hand
CF+ Cash Runway
Follow KMDA by email Get an email when KMDA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KMDA, unsubscribe in one click. Privacy

📣 What KMDA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cytomegalovirus Immune Globulin Intravenous… Cytomegalovirus Phase 4 · NCT06958796 Recruiting
Human Cytomegalovirus Immune Globulin Cytomegalovirus (CMV) Infection Phase 4 · NCT07009548 Enrolling by invitation
methylprednisolone or equivalent steroid Graft Versus Host Disease Phase 2/3 · NCT02956122 Terminated
KamRAB - HRIG Rabies Phase 3 · NCT02912845 Completed
Kamada-API Alpha 1-Antitrypsin Deficiency Phase 2/3 · NCT00460096 Completed
Kamada AAT for inhalation Emphysema Phase 2/3 · NCT01217671 Completed
Alpha-1-Proteinase Inhibitor Human Graft Versus Host Disease Phase 2/3 · NCT02956122 Terminated
Alpha-1-Antitrypsin Alpha 1-Antitrypsin Deficiency Phase 3 · NCT04204252 Terminated
Albumin Graft Versus Host Disease Phase 2/3 · NCT02956122 Terminated
Rabies Virus Strain Flury LEP Antigen… Rabies Phase 2/3 · NCT02040090 Completed
Kamada Anti-SARS-CoV-2 Covid19 Phase 1/2 · NCT04550325 Completed
Kamada-AAT for Inhalation, 160mg Alpha-1 Antitrypsin Deficiency Phase 2 · NCT02001688 Completed
Aerosolized, human, plasma-derived Alpha-1… Cystic Fibrosis Phase 2 · NCT00499837 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KMDA holds $75.3M in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KMDA files for a raise →

👥 Who Owns KMDA

Insiders 0.7% Other 5%+ holders 6% Institutions (77 holders) 49.4% Public and other holders 43.9%
HolderTypeShares% of sharesAs of
RECANATI LEON 5%+ holder (13G) 3,481,937 6.04% 2025-12-31
David Tsur
Director · +67,500 options
Insider 407,929 0.71% 2026-09-14
Yael Brenner
VP Quality · +60,000 options
Insider 6,266 0.01% 2026-09-14

Share count 57,686,056 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KMDA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KMDA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.